BACKGROUND: Glioblastoma multiforme (GBM), a high-grade glioma, is characterized by being diffuse, invasive, and highly angiogenic and has a very poor prognosis. Identification of new biomarkers could help in the further diagnosis of GBM. OBJECTIVE: To identify ELTD1 (epidermal growth factor, latrophilin, and 7 transmembrane domain-containing protein 1 on chromosome 1) as a putative glioma-associated marker via a bioinformatic method. METHODS: We used advanced data mining and a novel bioinformatics method to predict ELTD1 as a potential novel biomarker that is associated with gliomas. Validation was done with immunohistochemistry, which was used to detect levels of ELTD1 in human high-grade gliomas and rat F98 glioma tumors. In vivo levels of ELTD1 in rat F98 gliomas were assessed using molecular magnetic resonance imaging. RESULTS: ELTD1 was found to be significantly higher (P = .03) in high-grade gliomas (50 patients) compared with low-grade gliomas (21 patients) and compared well with traditional immunohistochemistry markers including vascular endothelial growth factor, glucose transporter 1, carbonic anhydrase IX, and hypoxia-inducible factor 1α. ELTD1 gene expression indicates an association with grade, survival across grade, and an increase in the mesenchymal subtype. Significantly high (P < .001) in vivo levels of ELTD1 were additionally found in F98 tumors compared with normal brain tissue. CONCLUSION: Results of this study strongly suggests that associative analysis was able to accurately identify ELTD1 as a putative glioma-associated biomarker. The detection of ELTD1 was also validated in both rodent and human gliomas and may serve as an additional biomarker for gliomas in preclinical and clinical diagnosis of gliomas.
BACKGROUND:Glioblastoma multiforme (GBM), a high-grade glioma, is characterized by being diffuse, invasive, and highly angiogenic and has a very poor prognosis. Identification of new biomarkers could help in the further diagnosis of GBM. OBJECTIVE: To identify ELTD1 (epidermal growth factor, latrophilin, and 7 transmembrane domain-containing protein 1 on chromosome 1) as a putative glioma-associated marker via a bioinformatic method. METHODS: We used advanced data mining and a novel bioinformatics method to predict ELTD1 as a potential novel biomarker that is associated with gliomas. Validation was done with immunohistochemistry, which was used to detect levels of ELTD1 in human high-grade gliomas and rat F98 glioma tumors. In vivo levels of ELTD1 in rat F98 gliomas were assessed using molecular magnetic resonance imaging. RESULTS:ELTD1 was found to be significantly higher (P = .03) in high-grade gliomas (50 patients) compared with low-grade gliomas (21 patients) and compared well with traditional immunohistochemistry markers including vascular endothelial growth factor, glucose transporter 1, carbonic anhydrase IX, and hypoxia-inducible factor 1α. ELTD1 gene expression indicates an association with grade, survival across grade, and an increase in the mesenchymal subtype. Significantly high (P < .001) in vivo levels of ELTD1 were additionally found in F98 tumors compared with normal brain tissue. CONCLUSION: Results of this study strongly suggests that associative analysis was able to accurately identify ELTD1 as a putative glioma-associated biomarker. The detection of ELTD1 was also validated in both rodent and humangliomas and may serve as an additional biomarker for gliomas in preclinical and clinical diagnosis of gliomas.
Authors: Stine N Clemmensen; Christina T Bohr; Sara Rørvig; Andreas Glenthøj; Helena Mora-Jensen; Elisabeth P Cramer; Lars C Jacobsen; Maria T Larsen; Jack B Cowland; Julia T Tanassi; Niels H H Heegaard; Jonathan D Wren; Asli N Silahtaroglu; Niels Borregaard Journal: J Leukoc Biol Date: 2011-12-20 Impact factor: 4.962
Authors: Howard Colman; Li Zhang; Erik P Sulman; J Matthew McDonald; Nasrin Latif Shooshtari; Andreana Rivera; Sonya Popoff; Catherine L Nutt; David N Louis; J Gregory Cairncross; Mark R Gilbert; Heidi S Phillips; Minesh P Mehta; Arnab Chakravarti; Christopher E Pelloski; Krishna Bhat; Burt G Feuerstein; Robert B Jenkins; Ken Aldape Journal: Neuro Oncol Date: 2009-10-20 Impact factor: 12.300
Authors: Gina Farias-Eisner; Anna M Bank; Brian Y Hwang; Geoffrey Appelboom; Matthew A Piazza; Samuel S Bruce; E Sander Connolly Journal: Br J Neurosurg Date: 2011-12-17 Impact factor: 1.596
Authors: Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape Journal: Cancer Cell Date: 2006-03 Impact factor: 31.743
Authors: Jeannette R Flynn; Libo Wang; David L Gillespie; Gregory J Stoddard; Jason K Reid; Jason Owens; Grant B Ellsworth; Karen L Salzman; Anita Y Kinney; Randy L Jensen Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: R A Towner; N Smith; S Doblas; Y Tesiram; P Garteiser; D Saunders; R Cranford; R Silasi-Mansat; O Herlea; L Ivanciu; D Wu; F Lupu Journal: J Cell Mol Med Date: 2007-01-09 Impact factor: 5.310
Authors: Siva K Gandhapudi; Chibing Tan; Julie H Marino; Ashlee A Taylor; Christopher C Pack; Joel Gaikwad; C Justin Van De Wiele; Jonathan D Wren; T Kent Teague Journal: J Immunol Date: 2015-03-16 Impact factor: 5.422
Authors: Rheal A Towner; Randy L Jensen; Brian Vaillant; Howard Colman; Debra Saunders; Cory B Giles; Jonathan D Wren Journal: Neuro Oncol Date: 2013-10-24 Impact factor: 12.300
Authors: Evgin Goceri; Behiye Goksel; James B Elder; Vinay K Puduvalli; Jose J Otero; Metin N Gurcan Journal: Int J Numer Method Biomed Eng Date: 2017-02-10 Impact factor: 2.747